NCT07480356Phase 3Recruiting

Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer

Study sponsor: Protara Therapeutics

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2028-04Estimated
Enrollment · participants284Estimated
Source updated2026-10-06Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Recruitment status changed

Before: Not yet recruiting. After: Recruiting.

Check registry source